While RET has proved to be an effective therapeutic target, resistant disease can develop in the face of RET-targeting tyrosine kinase inhibitors (TKIs) and options for systemic therapy of non-RET driven MTC are limited. This evidence concerns the gene RET and medullary thyroid gland carcinoma.